NJIT Implementation of Recent Executive Orders
DoD Peer Reviewed Medical Research Program, Technology/Therapeutic Development Award
Funding Agency:
- Department of Defense
The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC) is the program office managing this FY25 funding opportunity as part of the PRMRP. Congress initiated the PRMRP in 1999 to support medical research projects of clear scientific merit and direct relevance to military health. Appropriations for the PRMRP from FY99 through FY24 totaled $4.19 billion. The FY25 appropriation is $150M.
The vision of the PRMRP is to improve the health, care, and well-being of all military Service Members, and their Families and Veterans, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit that lead to impactful advances in health care of Service Members, Veterans, and their Families. The PRMRP challenges the scientific and clinical communities to address the congressionally mandated FY25 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and patient care.
3.1. Technology/Therapeutic Development Award History
The PRMRP first offered the TTDA mechanism in FY08. In FY21, the TTDA was offered with two funding levels based on the scope of research. In FY24, the PRMRP released the TTDA with only supported research in the final stages of preclinical development, previously referred to as Funding Level 2, and will continue to do so for FY25.
3.2. Intent of the Technology/Therapeutic Development Award
The PRMRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals. The proposed experiments may be hypothesis or milestone driven. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families. The product(s) to be developed under the FY25 PRMRP TTDA mechanism may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A “knowledge product” is a non-materiel product that addresses an identified need in a topic area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
The application’s direct costs budgeted for the entire period of performance should not exceed $2.5M.
$ 41,250,000
Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern Time (ET), June 9, 2025
11:59 p.m. ET, July 21, 2025
eBRAP Help Desk
301-682-5507